Sugi Predict

Sugi Predict / Compounds / SCHEMBL496099

SCHEMBL496099

SCHEMBL496099

CN1C(=O)CCc2ccc(N)cc21

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ATAD2 Q6PL18 2/20 0.51
▸ TRIM24 O15164 2/20 0.45
▸ HSD17B3 P37058 1/20 0.43
▸ CA9 Q16790 1/20 0.42
▸ CASP1 P29466 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ CYP11B1 P15538 4/20 0.41
▸ CYP11B2 P19099 4/20 0.41
▸ CYP19A1 P11511 2/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ CYP17A1 P05093 1/20 0.41
▸ BRD4 O60885 1/20 0.40
▸ ALOX5 P09917 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ TRPV1 Q8NER1 3/20 0.39
▸ SRD5A1 P18405 1/20 0.39
▸ CREBBP Q92793 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3597662 0.98 ATAD2 (0.50) ATAD2TRIM24HSD17B3CA9CASP1
SCHEMBL2062210 0.90 ATAD2 (0.44) ATAD2TRIM24HSD17B3CA9CASP1
SCHEMBL736131 0.86 ATAD2 (0.64) ATAD2TRIM24CASP1CASP7HSD17B10
SCHEMBL12991998 0.84 ATAD2 (0.41) ATAD2TRIM24CA9CYP19A1CREBBP
SCHEMBL10890659 0.80 TRIM24 (0.46) TRIM24CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL5023390 0.80 SRD5A1 (0.54) TRIM24HSD17B10CYP11B1CYP11B2CYP19A1
SCHEMBL12991995 0.79 ATAD2 (0.60) ATAD2HSD17B3CYP19A1BRD4TRPV1
SCHEMBL11263558 0.79 SRD5A1 (0.55) TRIM24HSD17B3CYP1A2CYP3A4TRPV1
SCHEMBL8556641 0.79 SRD5A1 (0.55) TRIM24CYP11B1CYP11B2CYP19A1CYP1A2
SCHEMBL6073803 0.79 PBRM1 (0.46) TRIM24CYP11B1CYP11B2CYP19A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1632477-B1 BENZAMIDE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2017-03-01 — — EP disclosed
EP-1632477-B1 BENZAMIDE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2017-03-01 — — EP disclosed
CN-103635458-B Trpv1 antagonists 艾伯维公司 2016-10-19 — — CN disclosed
US-8969325-B2 TRPV1 antagonists ABBVIE INC. (US) 2015-03-03 — — US disclosed
US-8969325-B2 TRPV1 antagonists ABBVIE INC. (US) 2015-03-03 — — US disclosed
US-8802711-B2 TRPV1 antagonists ABBVIE INC. (US) 2014-08-12 — — US disclosed
CN-103635458-A Trpv1 antagonists ABBVIE INC 2014-03-12 — — CN disclosed
EP-2688866-A1 TRPV1 ANTAGONISTS AbbVie Inc. (US) 2014-01-29 — — EP disclosed
US-20130172334-A1 TRPV1 ANTAGONISTS ABBVIE INC. (US) 2013-07-04 — — US disclosed
US-20130172334-A1 TRPV1 ANTAGONISTS ABBVIE INC. (US) 2013-07-04 — — US disclosed
US-20090270365-A1 such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics ASTELLAS PHARMA INC. (JP) 2009-10-29 — — US disclosed
US-20090270365-A1 such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics ASTELLAS PHARMA INC. (JP) 2009-10-29 — — US disclosed
US-20090270365-A1 such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics ASTELLAS PHARMA INC. (JP) 2009-10-29 — — US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 — — US disclosed
US-7585878-B2 Benzamide derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2009-09-08 — — US disclosed
US-7585878-B2 Benzamide derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2009-09-08 — — US disclosed
US-7585878-B2 Benzamide derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2009-09-08 — — US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 — — EP disclosed
US-20070167444-A1 Benzamide derivative or salt thereof ASTELLAS PHARMA INC. 2007-07-19 — — US disclosed
EP-1632477-A1 BENZAMIDE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2006-03-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172334-A1 TRPV1 ANTAGONISTS TRPV1, MRGPRX1, MRGPRX4 ATAD2 3776/4885TRIM24 4611/4885HSD17B3 4359/4885
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 ATAD2 231/4885TRIM24 2531/4885HSD17B3 4403/4885
US-20090270365-A1 such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics TRPV1, TRPV2, TRPV3 ATAD2 1997/4885TRIM24 1167/4885HSD17B3 3786/4885
US-20070167444-A1 Benzamide derivative or salt thereof TRPV1, BDKRB1, BDKRB2 ATAD2 1829/4885TRIM24 1873/4885HSD17B3 3083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.